Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.27 +3.9%	$9.97	$4.88 ▼ $19.58	$233.01M	N/A	22,720 shs	70,848 shs
ABCL AbCellera Biologics	$3.12 -1.3%	$2.36	$1.89 ▼ $3.68	$954.96M	0.36	3.19 million shs	7.38 million shs
AKBA Akebia Therapeutics	$3.50 -2.2%	$2.67	$0.80 ▼ $4.08	$934.98M	0.85	3.19 million shs	3.98 million shs
COLL Collegium Pharmaceutical	$29.44 -0.9%	$28.33	$23.23 ▼ $42.29	$937.61M	0.63	414,659 shs	580,756 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	+3.87%	-4.25%	+13.95%	+17.52%	+1,126,999,900.00%
ABCL AbCellera Biologics	-1.27%	+3.31%	+53.69%	+30.54%	+1.96%
AKBA Akebia Therapeutics	-2.23%	-10.71%	+34.10%	+23.24%	+233.33%
COLL Collegium Pharmaceutical	-0.91%	-3.06%	-2.61%	-1.37%	-7.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ABCL AbCellera Biologics	2.5191 of 5 stars	3.4	1.0	0.0	0.0	2.6	3.3	0.6
AKBA Akebia Therapeutics	4.0242 of 5 stars	3.6	2.0	0.0	4.0	3.2	0.8	0.6
COLL Collegium Pharmaceutical	3.8225 of 5 stars	3.4	1.0	0.0	3.0	2.2	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	177.28% Upside
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	167.09% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.75	92.86% Upside
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	48.61% Upside

Current Analyst Ratings Breakdown

Latest AARD, AKBA, COLL, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/1/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ABCL AbCellera Biologics	$28.83M	32.30	N/A	N/A	$3.58 per share	0.87
AKBA Akebia Therapeutics	$160.18M	5.74	N/A	N/A	($0.23) per share	-15.22
COLL Collegium Pharmaceutical	$631.45M	1.50	$12.47 per share	2.36	$7.10 per share	4.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.13	4.89	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)

Latest AARD, AKBA, COLL, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	25.86	25.86
ABCL AbCellera Biologics	N/A	10.15	10.15
AKBA Akebia Therapeutics	1.89	2.23	2.02
COLL Collegium Pharmaceutical	3.30	1.08	1.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ABCL AbCellera Biologics	61.42%
AKBA Akebia Therapeutics	33.92%
COLL Collegium Pharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ABCL AbCellera Biologics	28.90%
AKBA Akebia Therapeutics	3.00%
COLL Collegium Pharmaceutical	2.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable

AARD, AKBA, COLL, and ABCL Headlines

Recent News About These Companies

Exchange Traded Concepts LLC Decreases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 18 at 3:58 AM | marketbeat.com

1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your Radar

June 17 at 10:55 PM | msn.com

Assenagon Asset Management S.A. Sells 47,897 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 17 at 3:33 AM | marketbeat.com

John G. Freund MD At Collegium Pharmaceutical Decides to Exercises Options Worth $243K

June 12, 2025 | benzinga.com

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Sells $202,122.62 in Stock

June 12, 2025 | insidertrades.com

Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Sells 6,601 Shares of Stock

June 11, 2025 | marketbeat.com

COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities

June 10, 2025 | msn.com

Stocks To Watch: Dr. Reddy's Labs ADR Sees Relative Strength Rating Jump To 81

June 6, 2025 | msn.com

Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers

June 6, 2025 | msn.com

Wellington Management Group LLP Lowers Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 6, 2025 | marketbeat.com

1 Stock Under $50 with Exciting Potential and 2 to Turn Down

June 4, 2025 | finance.yahoo.com

Universal Beteiligungs und Servicegesellschaft mbH Invests $3.49 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 2, 2025 | marketbeat.com

Two Sigma Investments LP Sells 135,582 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 2, 2025 | marketbeat.com

Bank of America Corp DE Reduces Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 2, 2025 | marketbeat.com

Squarepoint Ops LLC Decreases Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

June 1, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 145,300 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

May 30, 2025 | marketbeat.com

Millennium Management LLC Raises Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

May 30, 2025 | marketbeat.com

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Ameriprise Financial Inc.

May 30, 2025 | marketbeat.com

Deutsche Bank AG Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

May 24, 2025 | marketbeat.com

Man Group plc Sells 122,142 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

May 23, 2025 | marketbeat.com

Jane Street Group LLC Sells 20,543 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, AKBA, COLL, and ABCL Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.27 +0.42 (+3.87%)

As of 06/17/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

AbCellera Biologics NASDAQ:ABCL

$3.12 -0.04 (-1.27%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.18 +0.05 (+1.76%)

As of 04:31 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Akebia Therapeutics NASDAQ:AKBA

$3.50 -0.08 (-2.23%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$3.50 +0.00 (+0.14%)

As of 04:26 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$29.44 -0.27 (-0.91%)

Closing price 06/17/2025 04:00 PM Eastern

Extended Trading

$29.44 0.00 (0.00%)

As of 06/17/2025 06:02 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time